ClinicalTrials.gg
CompletedNCT01017614Updated Nov 27, 2012

Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia

A Phase 3 interventional study of Monofer and Iron Sulphate in Inflammatory Bowel Disease, sponsored by Pharmacosmos A/S. Completed at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-27.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Inflammatory Bowel Diseases with a site in India — 3 open to participants now, 4 under way, 1 of them phase 3. Inflammatory Bowel Diseases · India.

Planned enrollment
7th of 14
350 · median 315
Started
2009
the only one that year
Phase 3
3 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
1 of 14
Pharmacosmos A/S

Among the 14 studies in Inflammatory Bowel Diseases with a site in India, this one is the 7th largest by planned enrollment, is the only one that started in 2009, is one of 3 in phase 3, and was the 2nd registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

3 of the 14 studies in Inflammatory Bowel Diseases with a site in India are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Inflammatory Bowel Diseases with a site in India, or all of them as a file.
02

Study summary

The purpose of the trial is to demonstrate that intravenous iron oligosaccharide is non-inferior to oral iron sulphate in reducing iron deficiency anaemia secondary to inflammatory bowel disease (IBD), evaluated as the ability to increase haemoglobin (Hb).

Read the detailed description

The study is designed to determine the effects of an investigational drug Monofer in subjects with Inflammatory Bowel Disease (IBD) (an intestinal disease characterized by swelling, redness and sometimes ulcers in intestine) and with Iron Deficiency Anaemia (IDA) (Anaemia is a condition characterized by deficiency of blood in the body).

03

Conditions studied

  • Inflammatory Bowel Disease

Keywords

  • Inflammatory Bowel Disease
  • Iron deficiency
  • Iron deficiency anaemia
  • Anaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects with a diagnosis of IBD with iron deficiency anaemia will be included if they meet all of the following criteria:

  1. Men and women, aged more than 18 years.
  2. Subjects diagnosed with inflammatory bowel disease and mild to moderate disease activity (defined as a score of less than or equal to 5 on the Harvey-Bradshaw index for Crohn's disease and a Mayo score (subscore without endoscopy) of less than or equal to 6 for ulcerative colitis).
  3. \<12.0 g/dL (7.45 mmol/L).
  4. Transferrin saturation (TfS) \<20 %.

Exclusion criteria

Exclusion Criteria:

  1. Anaemia predominantly caused by other factors than iron deficiency anaemia.
  2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis).
  3. Drug (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulphate).
  4. Known hypersensitivity to any in the drug products.
  5. Subjects with a history of multiple allergies.
  6. Active Intestinal Tuberculosis.
  7. Active Intestinal amoebic infections.
  8. Decompensated liver cirrhosis and hepatitis ( (ALT) > 3 times upper limit normal).
  9. Acute infections (assessed by clinical judgement), supplied with white blood cells (WBC) and C-reactive protein (CRP)).
  10. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
  11. Pregnancy and nursing
  12. Extensive active bleeding necessitating blood transfusion.
  13. Planned elective surgery during the study.
  14. Participation in any other clinical study within 3 months prior to screening.
  15. Intolerance to oral iron treatment.
  16. Untreated B12 or folate deficiency.
  17. Other I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit.
  18. Erythropoetin treatment within 8 weeks prior to screening visit.
  19. Diagnosis of and/or C, confirmed by appropriate lab test.
  20. Any other medical condition that, in the opinion of Investigator, may cause the patient to be unsuitable for the completion of the study or place the patient at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
  21. History of immunocompromise, including positive test result
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Monofer

    * administered as intravenous infusions (A1) * administered as intravenous bolus injections (A2)

    Drug: Monofer

  • Active comparator
    Iron Sulphate

    tablets administered orally

    Drug: Iron Sulphate

Interventions

  • * administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained * administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained

  • 200 mg daily

06

What researchers measure

Primary outcomes

  1. Change in Hb concentration from baseline to week 8.

    Time frame: 8 weeks

Secondary outcomes

  1. Number of subjects who achieve target limits of Hb (men 13-18 g/dL, women 12-16 g/dL) and have change in Hb concentration > 1.0 g/dL and have serum ferritin (100-800µg/L) and have achieved Transferrin saturation (TfS) (20-50 %) at week 2, 4 and 8.

    Time frame: 8 weeks

07

Study locations

10 sites
  • Research Site
    Aalborg, Denmark
  • Research Site
    Copenhagen, Denmark
  • Research Site
    Århus, Denmark
  • Research Site
    Hyderabad, India
  • Research Site
    Jaipur, India
  • Research Site
    Mumbai, India
  • Research Site
    Nasik, India
  • Research Site
    New Delhi, India
  • Research Site
    Pune, India
  • Research Site
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jul 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2009
First posted
Nov 20, 2009
Start
Oct 2009
Primary completionActual
Jul 2012
CompletionActual
Aug 2012
Last update
Nov 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01017614
Lead sponsor
Pharmacosmos A/S
Collaborators
Max Neeman International
First posted
Nov 20, 2009
Start date
Oct 2009
Primary completion
Jul 2012
Completion
Aug 2012
Last update
Nov 27, 2012

Study contacts

Pharmacosmos A/S
study chair · Pharmacosmos A/S, Roervangsvej 30, DK 4300 Holbaek, Denemark

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion